23 results on '"Croft, Brandon"'
Search Results
2. Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA
3. Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis
4. IMPACT OF AREA DEPRIVATION INDEX ON METHAMPHETAMINE-INDUCED PULMONARY ARTERIAL HYPERTENSION (MIPAH)
5. Possible cannabinoid-induced lactic acidosis requiring emergent dialysis.
6. Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children
7. Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis
8. Fournier Gangrene due to Sodium–Glucose Transport Protein-2 Inhibitor Use
9. Abstract OT1-03-06: Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)
10. Liposomes Modified with Superhydrophilic Polymer Linked to a Nonphospholipid Anchor Exhibit Reduced Complement Activation and Enhanced Circulation
11. Navtemadlin (KRT-232) in combination with avelumab for patients with anti-PD-1/L1 treatment-naïve TP53 Merkel cell carcinoma (MCC)
12. Clinical Outcome of Isolated Locoregional Recurrence in Patients With Breast Cancer According to Their Primary Local Treatment
13. An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer.
14. THE EFFECT OF ADMISSION DAY ON MORTALITY AND OTHER OUTCOMES IN PATIENTS WITH PULMONARY HYPERTENSION PRESENTING WITH COVID-19 INFECTION: A NATIONWIDE ANALYSIS
15. Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.
16. Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.
17. Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study
18. Risk Profiling of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients By Measuring Circulating Tumor DNA
19. Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study
20. Haloperidol undermining gastroparesis symptoms (HUGS) in the emergency department
21. Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children
22. Navtemadlin (KRT-232) in combination with avelumab for patients with anti-PD-1/L1 treatment-naïve TP53WTMerkel cell carcinoma (MCC)
23. Ubiquitin-Proteasome System in Neurodegenerative Disorders.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.